Fate Therapeutics vs Innate Pharma
FATE and IPHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FATE and IPHA compare
Fate Therapeutics grew revenue faster over the last twelve months (−33.4% versus −55.2% for Innate Pharma).
Fate Therapeutics scores higher on the StockData Score (6 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FATE | IPHA |
|---|---|---|
| Size and price | ||
| Market cap | $153M | – |
| Share price | $1.28 | $1.38 |
| Change, 1 year | 23.1% | −28.1% |
| Change, 5 years | −97.7% | −72.5% |
| Beta (5Y) | 2.42 | 0.93 |
| Employees | 161 | 181 |
| StockData Score | ||
| Total score | 6 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 32.3× | – |
| P/B | 1.2× | – |
| FCF yield | −69.7% | – |
| Fair value | $1.10 | – |
| Margin of safety | −16.5% | – |
| Growth | ||
| Revenue growth (TTM) | −33.4% (better) | −55.2% |
| Revenue growth, 5Y average | −26.7% (better) | −33.6% |
| Profitability | ||
| Operating margin | −2760% | −600% (better) |
| Net margin | −2620% | – |
| FCF margin | −2249% | −587% (better) |
| Return on equity | −67.8% | – |
| Return on invested capital | −1647% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −17.3× |
| Current ratio | 4.41 (better) | 0.60 |
| Altman Z-score | −9.92 | – |
| Piotroski F-score | 3 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 59.9% | 0.21% |
| Held by insiders | 25.7% | 16.2% |
| Insider net buying, 12 months | −$336K | – |
| Short interest, % of float | 11.2% | – |
Go deeper
- FATE stock overview
- FATE income statement
- FATE valuation and score
- IPHA stock overview
- IPHA income statement
- IPHA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.